$BGNE on NASDAQ
February 07, 2024
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
January 31, 2024
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)
December 22, 2023
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
December 21, 2023
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
November 29, 2023
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 28, 2023
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 21, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 17, 2023
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 09, 2023
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
BeiGene to Present at the Jefferies London Healthcare Conference
October 20, 2023
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 17, 2023
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
October 17, 2023
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
October 16, 2023
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
October 13, 2023
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
September 19, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
August 31, 2023
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
August 02, 2023
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
July 21, 2023
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
July 12, 2023
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
July 10, 2023
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
July 07, 2023
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
June 15, 2023
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
June 15, 2023
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
June 09, 2023
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
May 30, 2023
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
May 30, 2023
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults
May 25, 2023
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 24, 2023
BeiGene to Present at Upcoming Investor Conferences
May 17, 2023
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
May 06, 2023
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
May 04, 2023
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
April 26, 2023
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
April 25, 2023
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
April 20, 2023
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
April 17, 2023
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 13, 2023
BeiGene Expands Presence in Latin America With Opening of Brazil Office
March 30, 2023
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 21, 2023
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
February 27, 2023
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 24, 2023
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 06, 2023
Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemia
February 03, 2023
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 01, 2023
BeiGene to Present at Upcoming Investor Conferences
January 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
January 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
- No Recent Filings Found.
